Publication:
Thrombophilia and assisted reproduction technology-any detrimental impact or unnecessary overuse?

dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorAta, Mustafa Barış
dc.contributor.kuauthorUrman, Cumhur Bülent
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:07:54Z
dc.date.issued2016
dc.description.abstractThe aim of this study is to provide an overview of the studies investigating a possible association between thrombophilia and assisted reproductive technology (ART) outcome. This is a literature review. Congenital thrombophilias (CoT) are reported to be associated with pregnancy loss. However, the association between CoT and early pregnancy loss is weak and does not necessarily support causation. CoT are more likely to be associated with late fetal loss. Even though data pooled from case-control and cohort studies suggest an increased risk of ART failure in women with CoTs, there seems no association when the analysis is confined to better quality cohort studies. The evidence supporting anticoagulation to improve ART outcome in CoT carriers is weak. Likewise, studies on antiphospholipid antibodies (APAs) and ART outcome suffer from multiple methodological limitations and a detrimental impact of APA positivity is controversial. Empirical administration of heparin or low molecular weight heparin to women with recurrent ART failures is supported by weak evidence. Importantly, thrombophilias are likely to increase thrombotic complications after ovarian stimulation for ART. Current evidence does not support routinely testing for or treatment of thrombophilia in the setting of ART nor in couples with implantation failure. A careful personal and family history should be obtained and a risk assessment for thrombotic complications should be made in every woman undergoing ovarian stimulation. If positive, testing for thrombophilia is warranted.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue10
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume33
dc.identifier.doi10.1007/s10815-016-0771-8
dc.identifier.eissn1573-7330
dc.identifier.issn1058-0468
dc.identifier.scopus2-s2.0-84978806315
dc.identifier.urihttps://doi.org/10.1007/s10815-016-0771-8
dc.identifier.urihttps://hdl.handle.net/20.500.14288/9227
dc.identifier.wos386373200007
dc.keywordsAssisted reproduction
dc.keywordsThrombophilia
dc.keywordsHeparin
dc.keywordsPregnancy loss
dc.keywordsAntiphospholipid syndrome
dc.keywordsIn-vitro fertilization
dc.keywordsFactor-v-leiden
dc.keywordsRecurrent implantation failure
dc.keywordsMolecular-weight heparin
dc.keywordsEarly-pregnancy loss
dc.keywordsAntiphospholipid antibodies
dc.keywordsThrombotic events
dc.keywordsFetal loss
dc.keywordsWomen
dc.keywordsIVF
dc.language.isoeng
dc.publisherSpringer/Plenum Publishers
dc.relation.ispartofJournal of Assisted Reproduction and Genetics
dc.subjectGenetics and heredity
dc.subjectObstetrics and gynecology
dc.subjectReproductive biology
dc.titleThrombophilia and assisted reproduction technology-any detrimental impact or unnecessary overuse?
dc.typeReview
dspace.entity.typePublication
local.contributor.kuauthorAta, Mustafa Barış
local.contributor.kuauthorUrman, Cumhur Bülent
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files